- Home
- SRBK vs ACOG Comparison
SRBK vs ACOG Comparison
Compare SRBK & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- ACOG
- Stock Information
- Founded
- SRBK 1887
- ACOG 2000
- Country
- SRBK United States
- ACOG Canada
- Employees
- SRBK N/A
- ACOG N/A
- Industry
- SRBK
- ACOG
- Sector
- SRBK
- ACOG
- Exchange
- SRBK Nasdaq
- ACOG Nasdaq
- Market Cap
- SRBK 117.4M
- ACOG 129.6M
- IPO Year
- SRBK N/A
- ACOG N/A
- Fundamental
- Price
- SRBK $14.43
- ACOG $7.09
- Analyst Decision
- SRBK
- ACOG Strong Buy
- Analyst Count
- SRBK 0
- ACOG 1
- Target Price
- SRBK N/A
- ACOG $20.00
- AVG Volume (30 Days)
- SRBK 36.0K
- ACOG 97.9K
- Earning Date
- SRBK 10-31-2025
- ACOG 11-14-2025
- Dividend Yield
- SRBK 1.39%
- ACOG N/A
- EPS Growth
- SRBK N/A
- ACOG N/A
- EPS
- SRBK 0.61
- ACOG N/A
- Revenue
- SRBK $31,690,000.00
- ACOG $4,586,341.00
- Revenue This Year
- SRBK N/A
- ACOG N/A
- Revenue Next Year
- SRBK N/A
- ACOG $149.89
- P/E Ratio
- SRBK $23.58
- ACOG N/A
- Revenue Growth
- SRBK 38.91
- ACOG N/A
- 52 Week Low
- SRBK $10.54
- ACOG $3.75
- 52 Week High
- SRBK $15.46
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- SRBK 39.48
- ACOG 39.31
- Support Level
- SRBK $14.83
- ACOG $7.27
- Resistance Level
- SRBK $15.03
- ACOG $7.78
- Average True Range (ATR)
- SRBK 0.24
- ACOG 0.55
- MACD
- SRBK -0.08
- ACOG 0.01
- Stochastic Oscillator
- SRBK 0.97
- ACOG 34.25
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.